Application will increase clinical research awareness and raise money for over 20 medical causes
HORSHAM, Pa., January 19, 2009-Acurian, Inc., a leading provider of patient recruitment and retention solutions, announced today that it has released a new social networking application for clinical trial awareness and patient recruitment called Click it Forward. The company developed the application for the two most popular social networking platforms, Facebook and MySpace.
Acurian already maintains an active database of over 50 million individuals who have opted-in to receive new healthcare information, including clinical trial opportunities. According to Scott Connor, Acurian’s Vice President of Marketing, the launch of Click it Forward will serve to grow the database while also raising money for over 20 medical causes.
“Social networking is an ideal environment for promoting clinical trial awareness and increasing Acurian’s direct-to-patient recruitment capabilities,” explained Connor. “Facebook and MySpace together have nearly 200 million registered users, and we believe that Click it Forward plays well to these online audiences based on the application’s healthcare and altruistic characteristics.”
People register and install the free Click it Forward application on their Facebook or MySpace page, and then spread the application exponentially by inviting their online friends to install it. In doing so, they gain points based on how many friends subsequently install Click it Forward. The more points gained, the more money that Acurian donates to a selection of preferred medical causes selected by the user upon registration. The application also integrates Google Earth so that users can see a dynamic, visual map of their own Click it Forward network.
“Web 2.0 is driving real business opportunities in hundreds of industries, including healthcare,” continued Connor. “We are leveraging the platform to help our customers gain access to new patients, and in turn we are giving back to causes that will benefit from new therapies brought about through clinical research.”
To support the Click it Forward launch, Acurian has also launched a companion website at http://www.clickitforward.org.
About Acurian
Acurian is a leading full-service provider of clinical trial patient recruitment and retention solutions for the life sciences industry. Through its proprietary
patient panel of over 50 million patients, centralized advertising capabilities, and a fully hosted enrollment management technology platform, Acurian is able to identify, contact, prescreen, and refer patients into clinical trials, all while supporting investigator sites with services to maximize the randomization potential of every referred patient. Since 1998, Acurian has supported over 300 protocols for more than 60 companies. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
2 Commerce Drive
Cranbury, NJ 08512